DBVT
DBV Technologies S.A.
Set alert
- YTD
- -50.50%
- 1 year
- -32.65%
- Open
- 9.96
- Prev close
- 10.29
- Mkt cap
- 596.36M
- Vol
- 410.56K
- Avg vol
- 368.79K
- EPS
- -3.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.33
- High
- 10.13
- Forward P/E
- -35.12
- Beta
- -0.21
- Short ratio
- 5.37
- Inst. own
- 37.24%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 28, 2026
- 50-d avg
- 18.07
- 200-d avg
- 17.93
- 1y target
- 40.71
Key statistics
- Market cap
- 1.03B
- Enterprise value
- 700.74M
- Trailing P/E
- 0.00
- Forward P/E
- -35.12
- PEG ratio
- 0.00
- Price / sales
- 179.03
- Price / book
- 4.94
- EPS (TTM)
- -4.50
- Beta
- -0.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 5.74M
- Revenue growth
- 12.50%
- Free cash flow
- -87.21M
- Total cash
- 229.20M
- Total debt
- 6.10M
- Return on equity
- -158.89%
- Shares outstanding
- 59.19M
- Short % of float
- 2.41%
- 50-day average
- 18.07
- 200-day average
- 17.93
Analyst view
Consensus: buy
- Target (low)
- 5.82
- Target (mean)
- 40.71
- Target (high)
- 54.99
- Strong buy1
- Buy4
- Hold0
- Sell1
- Strong sell0
Next earnings
Oct 28, 2026
Expected Oct 28, 2026. Consensus EPS estimate -0.09367.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 28, 2026 | Sep 30, 2026 | -0.16141 | — | — | — |
| Jul 16, 2026 | Jun 30, 2026 | -0.12 | -0.1373 | -0.02 | -14.42% |
| Apr 30, 2026 | Mar 31, 2026 | -0.14 | -0.56 | -0.42 | -300.00% |
| Mar 27, 2026 | Dec 31, 2025 | -1.30 | -1.15 | +0.15 | +11.54% |
| Oct 28, 2025 | Sep 30, 2025 | -1.45 | -1.20 | +0.25 | +17.24% |
| Jul 29, 2025 | Jun 30, 2025 | -0.21 | -1.55 | -1.34 | -638.10% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 30, 2026 | Citizens | main | Market Outperform | Market Outperform |
| May 4, 2026 | Guggenheim | reit | Buy | Buy |
| May 1, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Mar 27, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Mar 27, 2026 | Guggenheim | reit | Buy | Buy |
| Dec 17, 2025 | HC Wainwright & Co. | main | Buy | Buy |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- dbv-technologies.com
News
- Guggenheim Maintains Buy on DBV Technologies, Lowers Price Target to $46
- Citizens Maintains Market Outperform on DBV Technologies, Lowers Price Target to $47
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- ServiceNow Posts Downbeat Q3 Earnings, Joins Sprouts Farmers Market, Alphabet And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
- DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript
- What DBV Technologies (DBVT) Said on Its Q3 Earnings Call
- DBV Technologies Q3 2026 Earnings Call Transcript
- DBV Technologies Q3 EPS $(0.14) Beats $(0.24) Estimate, Sales $1.600M Beat $820.000K Estimate
- DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
- DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
Your note
Sign in to keep a note on DBVT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MOHIDEEN PHARIS | Officer | Sale | Jan 28, 2026 | 144,995 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MPM Bioimpact LLC | 8.80% | 5,213,361 | 90.45M | Mar 30, 2026 |
| Vivo Capital, LLC | 4.51% | 2,667,569 | 46.28M | Mar 30, 2026 |
| Artisan Partners Limited Partnership | 3.75% | 2,219,386 | 38.51M | Mar 30, 2026 |
| Siren, L.L.C. | 3.14% | 1,857,362 | 32.23M | Mar 30, 2026 |
| Baker Bros. Advisors, LP | 2.47% | 1,461,425 | 25.36M | Mar 30, 2026 |
| Adar1 Capital Management, LLC | 1.71% | 1,012,866 | 17.57M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Artisan Partners Funds Inc.-Artisan International Small-Mid Fund | 2.30% | 1,363,189 | 23.65M | Mar 30, 2026 |
| RUSSELL INVESTMENT CO-Tax-Managed U.S. Mid & Small Cap Fund | 0.08% | 45,089 | 782.29K | Apr 29, 2026 |
| AdvisorShares Trust-AdvisorShares Dorsey Wright ADR ETF | 0.07% | 44,095 | 765.05K | May 30, 2026 |
| RUSSELL INVESTMENT CO-U.S. Small Cap Equity Fund | 0.04% | 22,707 | 393.97K | Apr 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.02% | 8,897 | 154.36K | May 30, 2026 |
| RUSSELL INVESTMENT FUNDS-U.S. Small Cap Equity Fund | 0.01% | 5,834 | 101.22K | Mar 30, 2026 |